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SCIENTIFIC OPINION 
Scientific Opinion on a Qualified Presumption of Safety (QPS) approach 
for the safety assessment of botanicals and botanical preparations
1
 
EFSA Scientific Committee
2, 3
 
European Food Safety Authority (EFSA), Parma, Italy 
 
ABSTRACT 
The Qualified Presumption of Safety (QPS) approach, initially developed for the assessment of microorganisms 
referred to EFSA and added to the food chain is equally applicable to the assessment of botanicals or botanical 
preparations. Using the principles to establish the suitability of a botanical preparation for QPS status, it has been 
possible to develop a structured assessment scheme that provides a practical method for assessing botanicals and 
botanical preparations for which an adequate body of knowledge exists and therefore without the need for further 
testing. Reiterative applications of the assessment scheme to related botanicals or different botanical preparations 
obtained from the same plant variety can allow a QPS status to be derived for specific groupings. However, the 
particularity of botanicals that may be presented in a wide variety of forms or whose morphology and chemical 
composition may be markedly affected by geographical and environmental factors, makes the possibility to 
establish QPS status at high taxonomic levels quite limited. Still, the above-mentioned structured approach for 
the assessment of botanicals and botanical preparations represents a considerable advancement in the 
development of a comprehensive, systematic and transparent methodology. The Scientific Committee 
recommends its use as an extension of the 2009 EFSA guidance for the safety assessment of botanicals and 
botanical preparations intended to be used in food supplements.  
© European Food Safety Authority, 2014 
 
KEY WORDS 
safety assessment, botanicals, botanical preparations, presumption of safety, QPS, assessment scheme 
                                                     
1  On request from EFSA, Question No EFSA-Q-2012-00642, adopted on 18 February 2014. 
2
 Scientific Committee members: Jan Alexander, Diane Benford, Qasim Chaudhry, Anthony Hardy, Michael John Jeger, 
Robert Luttik, Ambroise Martin, Bernadette Ossendorp, Simon More, Alicja Mortensen, Birgit Nørrung, Joe Perry, Iona 
Pratt†, John Sofos, Josef Schlatter, Kristen Sejrsen. Correspondence: scientific.committee@efsa.europa.eu 
3  Acknowledgement: The Scientific Committee wishes to thank the members of the Working Group on QPS, Andrew 
Chesson (Chair), Qasim Chaudhry, Luc Delmulle (until 7 August 2013), Birgit Dusemund, Karl-Heinz Engel, Kirsten 
Pilegaard, Ivonne Rietjens and Vittorio Silano for the preparatory work on this scientific opinion and EFSA staff: Bernard 
Bottex and Renata Leuschner for the support provided to this scientific opinion. 
 
QPS approach for the safety assessment of botanicals 
 
EFSA Journal 2014;12(3):3593 2 
SUMMARY 
The European Food Safety Authority (EFSA) asked the Scientific Committee to consider the 
applicability of the Qualified Presumption of Safety (QPS) approach for the safety assessment of 
botanicals / botanical preparations. 
The QPS approach was initially developed for the assessment of microorganisms referred to EFSA 
and added to the food chain; it requires four elements: i) the ability to establish the identity of the 
group of organisms considered, ii) the need for a sufficient body of knowledge to define its nature, iii) 
the consideration of possible pathogenicity and whether a qualification could be introduced to exclude 
pathogenic strains, and iv) information on the intended use. A basic tenet of the QPS approach as 
originally conceived was that suitability for the QPS approach should be established at the highest 
taxonomic level possible. 
The above-mentioned four elements are equally applicable to the QPS assessment of botanicals or 
botanical preparations. The particularity of botanicals that may be presented in a wide variety of forms 
or whose morphology and chemical composition may be markedly affected by geographical and 
environmental factors may introduce substantial compositional differences between preparations from 
the same plant species. As a result, the possibility to establish QPS status at high taxonomic levels will 
be quite limited. 
Using these principles, it has been possible to develop a structured assessment applicable to botanicals 
and botanical preparations used in food which took as its starting point the existing Guidance 
document on the safety assessment of botanical supplements that also introduces the concept of 
presumption of safety in its first assessment level.  
An exercise with examples showed that it is possible to create a list of plants for which a presumption 
of safety could be established. Data were collected for the purpose of this testing exercise only and are 
not the result of a structured data search. As such, the outcome of these QPS assessments should not 
be used elsewhere to support the safety of the botanicals and botanical preparations. For some 
botanicals, it may be possible to list individual species or groups of species from the same genus as is 
done for microorganisms, with the implication that use of the raw material or any extract of that 
material is presumed safe (subject to any qualifications). However, in contrast to the QPS list for 
microorganisms, the number of compounds of concern and their potential for differential extraction 
would mean that for other species only specific extracts could be included. As with microorganisms, 
exclusion from a QPS list would not imply a botanical or botanical preparation is unsafe, but that a 
case-by case assessment is required. 
In addressing the mandate provided, the Committee also considered, within the overall context of the 
EFSA safety assessment strategy, the value of making the necessary pre-assessments and developing a 
list of botanicals and botanical preparations which could be presumed safe. This opinion shows that 
the pre-assessment of a very large number of botanicals and their preparations would be demanding of 
resources and time. Where use is likely to be restricted to sensory purposes, the QPS approach offers 
only limited advantages over the existing methodologies and may not be cost-effective in the short 
term. Relatively few botanical preparations have multiple uses, particularly when feed applications are 
not considered. Consequently there are only a limited number of occasions when the same material is 
subject to assessment under different regulations and by different panels. The  few occasions when this 
does occur could be handled by normal processes within EFSA and would not justify establishing a 
QPS approach. 
Finally, it should be underlined that the structured approach for the assessment of botanicals and 
botanical preparations described in Figure 1 represents a considerable advancement in the 
development of a comprehensive, systematic and transparent methodology. The Scientific Committee 
recommends its use as an extension of the 2009 EFSA guidance for the safety assessment of botanicals 
and botanical preparations intended to be used in food supplements. Recommendation is made that 
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EFSA keeps track of the safety evaluations of specific botanical preparations in conformity with the 
methodology described in the present paper, as a comparison of such individual assessments may lead, 
in the future, to the establishment/enlargement of a specific QPS status. 
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BACKGROUND AS PROVIDED BY EFSA 
The evaluation of the safety and efficacy of botanicals is currently covered by several European 
regulations depending on their application (see Appendix A). The existing regulations on feed 
additives and on traditional medicinal products allow for an integrated assessment of botanicals and 
botanical preparations (looking both at safety and efficacy aspects). For food use, the responsibility for 
safety is left to the manufacturers and Member States‟ Competent Authorities, while EFSA has been 
charged with the evaluation of the scientific substantiation of claimed beneficial effects.  
Traditional use of botanicals and botanical preparations in a specific country has been the main basis 
for accepting the use of food supplements and/or traditional medicinal products and/or other products 
(e.g. teas and infusions).  
At present, EFSA is required to evaluate botanicals / botanical preparations in the following areas: 
 ANS: safety evaluation of botanicals / botanical preparations included in food supplements, 
safety evaluation of additives derived from botanical sources. 
 CEF: safety evaluation of botanicals / botanical preparations from non-food sources for 
flavouring applications; 
 FEEDAP: evaluation of safety and efficacy of around 300 botanicals with feed applications; 
 NDA: evaluation of 1548 botanical claims on hold until the European Commission clarifies 
which approach to take;  
The novel food regulation currently under revision (see Appendix A) implies that EFSA should have 
the capacity to quickly review the safety of botanicals which are “novel” for the European market, but 
have a history of safe use in their country of origin, and eventually raise safety objections that would 
call for a full safety assessment of the botanical.  
A number of tools and guidance have already been developed by EFSA for assessing botanicals and 
botanical preparations (see section 2). However, a generic assessment system allowing for priority 
setting among the botanicals the Panels have to evaluate has not been established. Such a generic 
assessment system should be transparent, consistent across the EFSA Panels, take account of the 
whole body of knowledge on a particular botanical, including its history of safe use, in order to focus 
resources on botanicals or botanical preparations presenting greater risks or uncertainties. 
 
TERMS OF REFERENCE AS PROVIDED BY EFSA 
The European Food Safety Authority requests the Scientific Committee to develop a generic 
assessment system allowing for priority setting among the botanicals the Panels have to evaluate. The 
system should be transparent, ensuring a consistent approach across the EFSA Panels, and take 
account of the whole body of knowledge on a particular botanical, including its history of safe use. 
The Scientific Committee is requested to perform this mandate in two steps: 
Develop a generic system for setting priorities among the botanicals to be assessed. For this purpose, 
the Scientific Committee is requested to consider:  
The guidance for the safety assessment of botanicals and botanical preparations intended for use as 
ingredients in food supplements (EFSA, 2009), which foresees that botanicals or botanical 
preparations for which an adequate body of knowledge exists could benefit from a “presumption of 
safety” without any need for further testing. 
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The applicability for botanical species of a Qualified Presumption of Safety (QPS) approach, similar 
to that developed for the assessment of selected microorganisms referred to EFSA and added to the 
food chain (EFSA, 2007). 
The generic system will be tested with several examples taken from the Compendium of botanicals 
reported to contain inherent substances of possible concern for human health (EFSA Scientific 
Committee, 2012b). Should the botanical genus or species considered contain substance(s) of possible 
concern, the possibility to identify a dose under which such substance(s) could be concluded as being 
of no concern will be explored. 
If deemed feasible and appropriate, define subsequent steps to develop a list of botanicals that are 
suitable for QPS status. 
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ASSESSMENT 
1. INTRODUCTION  
In 2007 EFSA formally introduced a novel system for the assessment of safety of microorganisms 
deliberately introduced into the food chain, based on a qualified presumption of safety (QPS) (EFSA, 
2007). This was done to avoid unnecessary duplication of efforts within EFSA and to aid the focussing 
of activities on those organisms likely to present the greatest risks. All potential candidate 
microorganisms were initially assessed for their suitability for inclusion in the system, independent of 
any specific authorisation process. A number of species were identified for which no safety concerns 
were found and these formed the basis of the QPS list. All strains identified as belonging to the listed 
species are then presumed safe without any further safety assessment. For some other species, a 
proportion of strains were recognised to present a specific hazard such as the ability to elaborate a 
toxin. Provided that a proven method existed to identify the hazardous strains (the qualification) then 
the species was also included in the QPS list. In this case only those strains which meet the 
qualification and are shown to be free of the recognised hazard are presumed safe. 
Four elements, referred to as pillars, were considered when establishing whether the QPS approach 
was suitable for a defined taxonomic group (e.g. genus or species) of microorganisms. First and 
foremost was the ability to establish identity. Without an unambiguous definition of the taxonomic 
unit under consideration it would not have been possible to connect to the remaining pillars of the 
assessment. The second pillar asked whether there was a sufficient body of knowledge based on 
published data and/or experience to exclude the likelihood of a hazard or, if identified, to define its 
nature. The third pillar was a consideration of possible pathogenicity and whether with existing 
knowledge a qualification could be introduced to be able to exclude pathogenic strains. The fourth and 
last pillar requires the assessment to take account of the intended use.  
The task of pre-screening of specific strains for use in the food chain was made easier by the relatively 
few microbial taxonomic units involved and by the increasing availability of genomic data and 
bioinformatics analysis assisting in identifying potential hazards. This, coupled with a history of use, 
i.e. significant human consumption, ideally over a period of several generations by a diverse 
population covering a wide range of genetic backgrounds and age groups, and the absence of clinical 
indications, allowed conclusions on the safety for defined taxonomic groups, with a high degree of 
certainty regardless of use. 
The QPS list of microorganisms is updated annually by the Panel on Biological Hazards. For strains 
belonging to taxonomic units excluded from the QPS approach, a case-by-case assessment is required. 
 
Botanicals and botanical preparations 
Recognising that concerns regarding the safety of botanical preparations used in food were widely 
raised in Member States, EFSA developed and published a guidance document that can be used for the 
safety assessment of botanicals and botanical preparations intended for use as ingredients in food 
supplements (EFSA, 2009). At the same time EFSA, in conjunction with Member States, began to 
develop a Compendium of Botanicals listing those plants reported to contain toxic substances or 
components that might otherwise be of concern (EFSA Scientific Committee, 2012b).  
The Guidance developed by EFSA describes a two tier approach in which the first level, described as 
Level A, is a safety assessment based on available knowledge. If the available data are considered 
inadequate to reach a sound conclusion on safety, Level B applies which foresees the generation of 
additional (toxicological) data. At Level A it may be concluded that a botanical or botanical 
preparation for which an adequate body of knowledge exists could benefit from a “presumption of 
safety” without any need for further testing. The knowledge needed to reach such a conclusion 
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resembles in some aspects that used to establish the suitability of microorganisms for the QPS 
approach. Both require a clear definition of the material being considered (first pillar in QPS for 
microorganisms) and familiarity including evidence of a history of safe use and the absence of any 
reported adverse effects (equivalent to second pillar in the QPS approach for microorganisms). 
However, it differs in one important respect from the approach taken with microorganisms. 
Conclusions on the safety of strains of microorganism included in the QPS are made without any 
restrictions on use or level of exposure. This is not the case with Level A which carries the restriction 
that “no significant increase of intake compared to historical levels is to be expected due to the 
intended levels of use in food supplements. This implies that not only use levels but also chemotypes 
of botanicals and the chemical compositions of the botanical preparations should be in line with those 
historically used. This approach can only be applied when intakes due to the intended levels of use are 
within the range of intake levels derived from the European Member States‟ average diets or from 
studies on specific subgroups. It is recognized that the acceptability of such an approach relies mainly 
on the objective of not significantly increasing exposures beyond the levels linked to the “(safe) 
history of use”. 
 
Application of QPS to botanicals and botanical preparations 
Both the Guidance and the Compendium are tools intended to aid the assessment of botanicals and 
botanical preparations. They are not intended to produce a list of botanicals and botanical preparations 
that might be presumed safe. However, those botanical preparations which satisfy the criteria laid 
down in Level A of the EFSA guidance could form the basis for a list akin to that developed for 
microorganisms thought suitable for a QPS approach. A QPS approach applicable to selected 
botanicals could offer advantages for much the same reasons as led to its development for 
microorganisms (e.g. avoiding repetitive assessments, ensuring consistency of approach, directing 
focus to the more hazardous items).  
The present opinion deals principally with botanicals and botanical preparations entering the food 
chain as food flavourings, food additives, as ingredients in food supplements, and as pesticides and 
biocides. A summary of the regulatory frameworks applicable to botanicals is provided in Appendix 
A. This opinion does not address the use of botanicals and botanical preparations in animal feed for 
two reasons. Firstly, whole plant material is considered a feed material and as such is excluded from 
any requirement for a safety assessment. Secondly, while plant extracts are considered feed additives 
and do require formal assessment, the considerable differences in absorption, distribution, metabolism 
and excretion found amongst livestock including fish makes it unlikely that a composite conclusion 
necessary for a QPS approach could be achieved.  
In addressing the mandate provided, the Committee first considered the criteria to establish the 
suitability for a QPS approach to assess the safety of botanicals and how a structured judgement might 
be made. This took as its starting point the level A of the Guidance document for the safety assessment 
of botanicals, but where possible extended its scope beyond the constraint imposed by historical levels 
of exposure. A number of practical examples were then selected to test the applicability of the 
proposed methodology. Finally, the costs and benefits of making the necessary pre-assessments and 
developing a list of botanicals and botanical preparations which could be presumed safe were 
considered within the overall context of the EFSA safety assessment strategy.  
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2. EFSA GUIDANCE DOCUMENTS FOR THE SAFETY ASSESSMENT OF BOTANICALS AND 
BOTANICAL PREPARATIONS INTENDED FOR USE AS INGREDIENTS IN FOOD SUPPLEMENTS 
The Scientific Committee focussed its work on botanicals and botanical preparations, including food 
supplements; the proposed approach for safety assessment is however applicable to other uses of 
botanicals and botanical preparations in the food and feed areas. The guidance of the Scientific 
Committee for the safety assessment of botanicals comprises:  
 a list of technical, exposure and toxicological data needed to assess the safety of botanical 
ingredients.  
 a two-steps approach for safety assessment.  
The first level (level A) of the two-steps approach described in the SC Guidance (EFSA, 2009) makes 
use of the information on history of safe food use in Europe and the above-mentioned data directly 
available from the literature. Provided that no significant increase of intake compared to historical 
levels of intake of the botanical ingredient under consideration is expected due to the intended level of 
use in food supplements and whenever available data would demonstrate that exposure to known 
levels of the botanical ingredient has occurred in large population groups for many years without 
reported adverse effects, a presumption of safety may be applied to the considered preparation without 
any further request for testing. Botanicals reported to contain substances of concern (see EFSA 
Compendium of botanicals reported to contain naturally occurring substances of possible concern for 
human health when used in food supplements (EFSA Scientific Committee, 2012b) could also be 
granted presumption of safety provided that intake remains below an acceptable health-based guidance 
value.  
Exposure to the substance(s) of concern can also be considered in relation to the Threshold of 
Toxicological Concern (TTC) values. The EFSA Scientific Committee evaluated in 2012 the TTC 
approach as a tool for providing scientific advice about possible human health risks from low level 
exposures and its applicability to EFSA‟s work (EFSA Scientific Committee, 2012c). The opinion of 
the Scientific Committee identified however a number of (categories of) substances for which the TTC 
approach should not be used:  
 High potency carcinogens (i.e. aflatoxin-like, azoxy- or N-nitroso-compounds, benzidines, 
hydrazines). 
 Inorganic substances 
 Metals and organometallics 
 Proteins 
 Steroids 
 Substances that are known or predicted to bioaccumulate 
 Nanomaterials 
 Radioactive substances 
 Mixtures of substances containing unknown chemical structures 
The EFSA Panel on Food Additives and Nutrient Sources added to Food (ANS Panel), in its guidance 
document on the scientific data required to be submitted for food additive evaluations (EFSA ANS 
Panel, 2012) refers to the SC guidance for the safety assessment of botanicals and botanicals 
preparations (EFSA, 2009) for the assessment of additives derived from botanical sources. The ANS 
guidance gives the possibility for botanical food additives derived from conventional food sources 
with a long history of food use to benefit from a “presumption of safety” under certain circumstances 
when an adequate body of knowledge exists. The Panel took note of the requirement in the SC 
guidance on botanicals that “no significant increase of intake compared to historical levels is to be 
expected due to the intended levels of use” and further clarified that the definition of what is 
considered a significant increase, compared to historical levels, should be judged on a case-by-case 
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basis, as this implies that not only use levels but also chemotypes of botanicals and the chemical 
compositions of the botanical preparations should be in line with those historically used.  
In cases where the anticipated intake of the botanical ingredient is significantly higher than the 
estimated historical intake level, or where no historical intake level could be identified, the SC 
guidance on botanicals requires that additional exposure data are provided and assessed under the 
second level (level B) of the assessment. Where it was not possible to conclude on presumption of 
safety at the level A assessment because of lack of data on some toxicological aspects, additional 
toxicological studies should be carried out and assessed under level B as well. Both the SC and the 
ANS guidance documents describe the type of studies needed in relation to the different toxicological 
endpoints (EFSA, 2009; EFSA ANS Panel, 2012).  
For compounds that are genotoxic and carcinogenic, the Scientific Committee recommends the 
Margin of Exposure (MOE) approach (EFSA, 2005); the Scientific Committee clarifies in its opinion 
that substances which are both genotoxic and carcinogenic should not be deliberately added to foods 
but does not mention specifically how to address naturally occurring genotoxic and carcinogenic 
substances in botanicals or botanical preparations that have a long tradition of food use. In a follow-up 
statement published in 2012, The Scientific Committee clarified that the recommendation to use the 
MOE approach holds true also for impurities, such as unavoidable contaminants, residuals and by-
products resulting from a production process (EFSA Scientific Committee, 2012a). In the case of 
impurities, breakdown and reaction products, metabolites, and low-level contaminants in food where 
an exposure assessment can be conducted, but on which there are few or no toxicological data, both 
the Scientific Committee and the ANS Panel suggested the use of the TTC approach (EFSA ANS 
Panel, 2012, EFSA Scientific Committee, 2012c). 
 
Determining the suitability of a botanical or a botanical preparation for inclusion in a QPS list 
It is recognised that there are significant differences in the assessment of botanicals compared to 
microorganisms which must be taken into account when assessing the suitability of a QPS approach to 
botanicals and botanical extracts. Relatively few microbial species are used by the food/feed industries 
compared to the many hundreds of botanical species. Similarly microorganisms are fed as live 
organisms not subject to further treatment while botanicals may be presented in a wide variety of 
forms (e.g. different parts and extracts) introducing substantial compositional differences between 
preparations from the same botanical species.  
A basic tenet of the QPS approach as originally conceived was that suitability for the QPS approach 
should be established at the highest taxonomic level possible. For botanicals it is difficult to apply this 
principle. Many genera of plants contain hundreds of species/subspecies, few of which are fully 
characterised and consequently any pre-assessment may well be limited to a single species or even an 
extract or a specific part of a plant. In addition, morphology and chemical composition of plants may 
be markedly affected by geographical and environmental factors, not least from the selection of 
cultivars appropriate for a given region. All of these factors will influence the possibilities for 
grouping of botanicals and botanical preparations in a QPS approach and influence the decision on 
what materials can be included in the assessment. 
Figure 1 presents a flow chart with a possible approach for the assessment of botanicals and/or 
botanical preparations, based on the data available, i.e. without requesting any testing. Given that the 
proposed approach is based on the data available without any further additional testing, it is basically 
in line with the so-called Level A assessment described in the SC guidance for the safety assessment 
of botanicals and botanical preparations (EFSA, 2009) and allows to eventually conclude on 
presumption of safety. The diagram includes various steps and should be applied in an iterative way 
considering upon finalising the QPS evaluation for one preparation whether other preparations or even 
preparations of related botanical species can be included. The next section describes in further details 
the various steps of the proposed approach for the QPS assessment of botanicals and/or botanical 
preparations.  
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Figure 1:  Flow diagram of the proposed methodology for QPS assessment of botanicals and botanical preparations. 
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Step 1: Defining the botanical species, part(s) of plant and preparation(s) of interest  
In a first step, it has to be defined what plant species and what plant part(s) and type of preparation(s) 
are to be assessed. Given the large variation in composition that may exist between different 
subspecies/varieties of a botanical species, between a botanical grown under different environmental 
conditions, between different parts of the same botanical, and between preparations made using 
different manufacturing processes, -for example different extraction methods leading to different 
substances being extracted-, it is important to carefully define at the very beginning the botanical 
species and (part)s of the plant and preparations evaluated. Guidance on how to do this can be found in 
the previous EFSA opinion defining guidance on the safety assessment of botanical and botanical 
preparations intended for use as ingredients in food supplements (EFSA, 2009).  
 
Step 2: Evaluating the compositional / toxicological / use data 
In the second step, one should review the available data on the composition and toxicity of the 
botanical or botanical preparation as well as its constituents. Adequate compositional, use, and 
toxicological data should be collected in line with what has been described before in the Guidance on 
safety assessment of botanicals and botanical preparations intended for use as ingredients in food 
supplements (EFSA, 2009). The history of use should also be considered as part of the body of 
knowledge in line with the level A evaluation described in this Guidance. This knowledge can be 
especially of importance if the evaluation according to the decision tree in Figure 1 would lead to 
acceptance of only unrealistically low exposure levels compared to historical use levels. This process 
of data collection should define all biologically active substances described in the literature that have 
been identified in the botanical or botanical preparation, also including their actual levels. It is 
essential to define the percentage of the material that has been characterised, and what percentage of 
the preparation evaluated remains unidentified. In this process of identifying substances of concern 
other sources of data suggesting possible adverse effects and toxicity linked to the botanical or 
botanical preparation under evaluation must be included. Information on substances of concern can 
relate to isolated substances but can also be derived from data on the extract itself. If available, data on 
matrix and combination effects may also be taken into account when defining substances of possible 
concern. 
Furthermore, the possibility of cross contamination from one part of the plant with compounds of 
concern to other parts of the same plant should also be considered. An example is the presence of 
morphine and codeine usually detected in Papaver somniferum L. (opium poppy) seed samples due to 
contamination with the latex or other parts of the plant (EFSA CONTAM Panel, 2011) 
If compositional / toxicological / use data are available these data are evaluated in the next step. 
 
Step 3: Evaluating the compositional / toxicological data 
Once the available and relevant compositional and toxicological data are defined this may result in 
five possible situations, reflected in Figure 1 (from right to left): 
The chemical characteristics of the botanical or botanical preparation are adequately defined and no 
adverse effects are reported. In such situations presumption of safety may be assigned without the 
need to introduce any qualifications, such as defining the exposure limit for which the QPS status 
holds.  
The botanical or botanical preparation contains substances with known structures but unknown 
toxicity profiles. In such situations one may investigate whether based on validated in silico or read-
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across approaches adequate predictions can be generated without the need for further toxicological 
testing. If the in silico and/or read-across approaches do not give results suitable for subsequent risk 
assessment, the botanical or botanical preparation will require further toxicological testing and has to 
be excluded from the QPS approach until additional data have been provided. In case in silico or read-
across methods can generate information on the substances with known structures but unknown 
toxicity profiles, the botanical preparation may be granted QPS status without qualification, provided 
chemical characterisation was adequate and there were no reports on adverse effects. In the case where 
in silico and read-across methods identified possible toxicity, the substance becomes a “substance of 
concern” and the preparation shall then be evaluated for possible QPS status following the approach 
described in the next bullet point. The in silico predictive models are essentially based on structure-
activity relationship (SAR), quantitative structure-activity relationship (QSAR), or a read-across 
between a group of analogous compounds that have structural and/or functional similarities to the 
untested compound. A wide range of methods and tools is already available for in silico toxicological 
profiling of a wide range of chemical substances, and can also be useful for compounds from botanical 
or other natural sources. Expert systems, on the other hand, can combine different in silico approaches 
to predict toxicity of a chemical substance from its structure. These may comprise decision-trees based 
on rules, structural alerts, and/or nested (Q)SARs. The (Q)SAR models are only reliable when they are 
tested rigorously for robustness and predictivity and their „applicability domain‟ is clearly defined. In 
regard to in silico estimation of toxicity of botanicals, the issue remains of how to assess such a 
mixture where more than one main components are of unknown toxicological significance. Until 
recently (Q)SAR and other in silico methods have not been considered useful tools for such 
assessments, but work is ongoing to allow for the read-across assessment of mixtures. Finally it should 
be underlined that the use of the (Q)SAR models, expert systems, read-across tools, etc would need a 
clearly identified chemical structure, which may be a limiting factor for the application of the 
approach to botanicals and botanical preparations for which only limited analytical data are often 
available. 
The botanical or botanical preparation contains substance(s) of concern. When the substance is acting 
by a thresholded mode of action (MOA), the exposure resulting from the use of the botanical or 
botanical preparation must be evaluated against established health based guidance values, using a 
Margin of Safety (MOS) approach, or compared to available toxicity data or data on the history of safe 
use at specific exposure levels to define a safe level of intake. This safe level of intake can be taken as 
the basis to define QPS with a qualification defining the exposure limit for which the QPS status 
holds. If for the substance(s) of concern with a thresholded MOA, no health based guidance values or 
toxicity data enabling definition of a safe level of intake are available, one may apply the TTC concept 
(EFSA Scientific Committee, 2012c) to define an exposure qualification to be linked to the QPS 
status. Application of the TTC approach requires that the chemical structure of the substance(s) with 
unknown toxicity profile is defined. It is noted that, with the exception of flavour use, application of 
the TTC approach may often result in exposure qualifications for the QPS status that are far below the 
proposed uses and use levels of the botanicals or botanical preparation of interest finally resulting in 
excluding the relevant botanicals or botanical preparations from the QPS approach. If a safe level of 
intake for substance(s) of concern cannot be established, the botanical or botanical preparation cannot 
be assigned a QPS status. This is the case for substance(s) acting by a non-thresholded MOA, e.g. 
genotoxic and carcinogenic substances. The Margin of Exposure (MOE) approach (EFSA, 2005; 
EFSA Scientific Committee, 2012a) may be applied to define their level of concern but, given the 
recommendation of the Scientific Committee to not introduce in the food chain substances that are 
known to be genotoxic and carcinogenic (EFSA, 2005), these substances will be excluded from the 
QPS approach and therefore subject to a case-by-case assessment. 
The botanical or botanical preparation has been linked to adverse effects but compounds of concern 
are not identified. In this situation one may base the QPS decision on data available on the history of 
safe use at traditional exposure levels, provided that the adverse effects reported occurred at non-
traditional levels of use. If such data are not available, the botanical or botanical preparation should be 
excluded from the QPS approach. If data on the history of safe use at defined traditional exposure 
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levels are available, these traditional exposure levels can form the basis to define a QPS status with 
qualifications. 
The final possible outcome may be that the botanical or botanical preparation contains a fraction of 
uncharacterised substances. This may often be the case since full chemical characterisation of a 
botanical or botanical preparation may often not be available. In such situations one may also base the 
QPS decision on the available data on history of safe use at traditional exposure levels. If such data are 
not available the botanical or botanical preparation should be excluded from the QPS approach. If data 
on the history of safe use at defined traditional exposure levels are available these traditional exposure 
levels can form the basis to define a QPS status with qualifications. 
 
Products commonly eaten are presumed safe unless a significant risk has been identified. Absence of 
evidence of toxicity, however, is not necessarily evidence of absence of toxicity under the proposed 
conditions of usage (e.g. long-term use of herbal preparations). Therefore, when considering history of 
use and accumulating the body of knowledge describing the safety profile of a botanical preparation, a 
number of important factors should be considered where available: the period over which the 
traditional preparation has been consumed, the way it has been prepared and used and at what intake 
levels, known limitations and restrictions for sensitive populations, its composition, the results of 
animal studies, observations from human exposure and clinical reports (Constable et al. 2007).  
 
Step 4: Repeating the steps in an iterative process  
When positive conclusions on safety have been reached, either with qualifications or not, after 
evaluating a specific botanical preparation, it may be relevant to repeat the process in an iterative way 
to other species / plant parts/ preparations. This step 4 should therefore include a consideration about 
whether there are similar preparations from other subspecies/varieties/ species for which the 
assessment could be relevant and if the safety evaluation could be extended to other preparations from 
other species/varieties, thus extending the number of botanical preparations for which the QPS status 
would hold. Considering which other botanical species/varieties and/or preparations could be covered 
by the specific safety evaluation can best be done starting from the chemical compositions. In fact, if 
the chemical compositions obtained from different species/varieties/plant parts or preparations are 
similar it would be reasonable to extend the safety evaluation obtained initially. This might be possible 
even if some quantitative differences would be detected among the chemical compositions. In 
addition, the described safety assessment procedure could be applied in an iterative manner, starting 
with evaluation of one botanical and/or botanical preparation and subsequently considering the 
feasibility of expanding the conclusion(s) obtained to other species/varieties or botanical preparations. 
The grouping should preferably include plants relevant for food consumption and with a history of 
safe use. It is also important that the botanical species and preparations evaluated are chosen as broad 
as possible, although it is acknowledged that evaluation at the species level may often be hampered by 
the wide variability between related varieties within a species. In some cases QPS may be granted for 
a single preparation and no extension or iteration is possible hampering the suitability of the QPS 
approach at higher taxonomic levels. 
 
3. TESTING THE SUITABILITY OF THE QPS APPROACH FOR BOTANICALS 
The present section aims at testing the proposed approach for the QPS assessment of botanicals and 
botanical preparations with selected case studies. Data were collected for the purpose of this testing 
exercise only and are not the result of a structured data search. The outcome of this assessment should 
not be used elsewhere to support the safety of the botanicals and botanical preparations. Further details 
on the data considered and how the flow diagram (Figure 1) was used for the QPS assessment of the 
selected case studies can be found in Appendix B.  
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There are species and genera for which compositional data exist but for which the Compendium and 
other sources do not identify substances of concern. One example is the fruit (hips) and petals of Rosa 
canina and related species. There is a long history of human consumption and more recently hips in 
concentrated form have been used in food supplements with a variety of claimed benefits, not all 
related to the recognised high concentration of vitamin C. Since a search revealed no reported adverse 
effects, apart from digestive tract and mouth irritation resulting from the ingestion of the hair-like 
layer under the flesh of the hips, the structured assessment in Figure 1 would lead to the outcome that 
R. canina fruit and petal could be included in a QPS list without qualifications. Repeating the process 
for other Rosa species would add to the list.  
Citrus also represents a genus for which extensive data on the composition of the fruit, peel, and 
essential oils derived from them can be found for some species. However, unlike Rosa spp. the 
Compendium and the open literature identify the presence of linear furocoumarins with recognised 
phototoxic effects as compounds of concern in essential oils of many Citrus spp. Because of the use of 
such compounds in the oral treatment of skin diseases, their toxicokinetics are known and long and 
short term toxicity studies exist. From Figure 1 it is probable that sufficient toxicity data exist which 
would allow many Citrus spp to be included in a QPS list with a qualification relating to the linear 
furocoumarin content. However for a few Citrus spp., notably Citrus aurantium, a further compound 
of concern has been identified; animal experimental studies and human data have shown that Citrus 
aurantium extracts can induce cardiovascular effects, ascribed to the presence of (-)-synephrine. 
Following Figure 1, (-)-synephrine is a thresholded substance for which no health-based guidance 
value was set. Since the existing toxicity data are insufficient to derive such a value, use of extracts of 
Citrus aurantium in food supplements would have to be restricted to levels where no significant 
increase of (-)-synephrine exposure compared to historical intake levels with traditional foods is to be 
expected. Thus Citrus exemplifies a genus for which different conclusions with regard to a QPS 
approach would be reached for different species. 
Rosmarinus officinalis was selected because it represents a case where, although only a single species 
is generally used, many different preparations and extracts are used each with substantially different 
compositions. Unusually, non-aqueous extracts of rosemary leaves have already been assessed for 
safety by EFSA. This resulted in a QPS-like conclusion that non-aqueous extracts were safe for use in 
food provided a qualification that the carnosic acid plus carnosol content remained within specified 
limits was observed. Although the Compendium identifies only monoterpenes as compounds of 
concern, which are poorly soluble in water, aqueous extracts contain very high concentration of 
rosmarinic acid. The very limited available toxicity data for rosmarinic acid do not suggest a hazard 
but are insufficient to derive a threshold value. A QSAR approach may solve this issue and could 
allow a QPS listing without qualification. The essential oil of Rosemary has a high monoterpene 
content, notably camphor. The traditional use of rosemary for abortion, coupled with preliminary 
evidence showing embryotoxic effects of the oil is cause for concern. Additionally, the oil provokes 
genotoxic and mutagenic effects when administered orally. Consequently the essential oil is not 
suitable for food use. Thus assessment of rosemary and its various extracts show that a composite 
conclusion on the species is not possible and that any QPS listing could apply only to specific extracts.  
Foeniculum vulgare (fennel) and Ocimum tenuiflorum (holy basil) present similar issues as both 
contain the genotoxic and carcinogenic agent estragole. Given the recommendation of the Scientific 
Committee to not introduce in the food chain substances that are known to be genotoxic and 
carcinogenic (EFSA, 2005), Foeniculum vulgare and Ocimum tenuiflorum are excluded from the QPS 
approach. For risk management purposes, it may be of interest to assess preparations of these species 
on a case-by-case basis, using the carcinogenicity data for estragole from which a BMDL10 could be 
derived and for which it is therefore possible to apply the MOE approach. The fact that some 
preparations e.g. essential oils of Foeniculum vulgare and Ocimum tenuiflorum species will show 
higher levels of estragole than the levels extracted into (traditional) water based preparations should 
then be taken into account. For preparations other than the essential oil of Ocimum tenuiflorum, there 
is an additional concern related to reproductive effects. Since the chemical(s) of concern for the 
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reproductive effects have not been identified and as the compositional data are limited, this is an 
additional argument to exclude extracts of O. tenuiflorum from QPS listing. 
Young leaves and leaf buds of Camellia sinensis are used unfermented and dried to produce traditional 
“green tea” as the basis for traditional aqueous green tea infusions and for the manufacturing of dried 
green tea extracts for food supplement use. Although there are no significant health concerns 
associated with traditional consumption of green tea infusions, in recent years an association was seen 
between the intake of larger amounts of dried green tea extracts via food supplements to support 
weight-loss and the occurrence of liver damage. One component of green tea extracts, (-)-
epigallocatechin-3-gallate (EGCG), the major catechin present, is associated with liver toxicity seen in 
animals and humans. EGCG is a thresholded substance with sufficient toxicity data to establish a 
health-based guidance value. Consequently dried green tea extracts from Camellia sinensis, following 
the scheme outlined in Figure 1 could be included in a QPS list with a qualification to protect against 
exposure to EGCG greater than the guidance value. 
 
The exercise above shows that it would be possible to create a list of plants for which a presumption of 
safety could be established. For some botanicals, it may be possible to list individual species or groups 
of species from the same genus as is done for microorganisms, with the implication that use of the raw 
material or any extract of that material is presumed safe (subject to any qualification). However, in 
contrast to the QPS list for microorganisms, the number of compounds of concern and their potential 
for differential extraction would mean that only specific extracts could be included. 
 
4. VALUE FOR EFSA 
It has to be acknowledged that the pre-assessment of a very large number of botanicals and their 
preparations would be demanding of resources and time. Where use is likely to be restricted to sensory 
purposes the QPS approach, while possible, offers only limited advantages over the existing 
methodologies. Relatively few botanical preparations have multiple uses, particularly if feed 
applications are not considered. Consequently there are only a limited number of occasions when the 
same material is subject to assessment under different regulations and by different panels. Such few 
cases could be handled by normal processes within EFSA.  
One of the major benefits of the QPS approach applied to microorganisms is that the presumption of 
safety could be applied to strains falling within a defined taxonomic unit regardless of intended use. A 
parallel situation for botanicals would be more rarely encountered and the scope of application for 
those materials listed is likely to be more restrictive. Inevitably this reduces the value of the QPS 
approach to safety assessment, as some applications may be covered by the pre-assessment and others 
not. 
 
CONCLUSIONS AND RECOMMENDATIONS  
CONCLUSIONS 
The principles used to establish the suitability of a microbial group for inclusion in a QPS list of 
microorganisms can be applied in a similar manner to botanicals and botanical preparations. However, 
the particularity of botanicals, which may be presented in a wide variety of forms and whose 
morphology and chemical composition may be markedly affected by geographical and environmental 
factors, makes the possibility of establishing QPS status at high taxonomic levels quite limited. 
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Using the above-mentioned principles, it has been possible to develop a structured assessment scheme 
(see Figure 1) applicable to botanicals and botanical preparations used in food which took as its 
starting point the existing EFSA Guidance document on the safety assessment of botanical 
supplements. 
Reiterative applications of the structured safety assessment scheme to related botanicals or different 
botanical preparations obtained from the same plant variety can allow a Qualified Presumption of 
Safety status to be derived for specific botanical groupings.  
When granting QPS status on the basis of history of use in the absence of reported adverse effect, it 
should be kept in mind that absence of evidence for adverse effect can not be taken as an evidence for 
the absence of adverse effect(s). The suitability for QPS status of e.g. preparations containing 
substances that show a pharmacological effect at doses close to the levels of exposure resulting from 
the traditional use should be carefully considered, as there is a biological plausibility for an adverse 
health effect, although it has not been picked up by historical data. 
The exercise with examples carried out in the present opinion showed that it is possible to identify 
some plant species suitable for inclusion in a QPS list as is done for microorganisms. However, for 
other plants, because of the number of compounds of concern and their potential for differential 
extraction, only specific extracts were considered suitable for inclusion.  
As with microorganisms, exclusion from a QPS list would not imply a botanical or botanical 
preparation is unsafe, but that a case-by case assessment of safety is required. 
The use of botanicals and botanical preparations in animal feed is excluded from consideration at this 
stage. The lack of category-specific data and the potential differences in pharmacokinetics found 
amongst livestock including fish makes it unlikely that a composite conclusion necessary for a QPS 
approach could be achieved.  
Relatively few botanical preparations have multiple uses, particularly when feed applications are not 
considered. Consequently there are only a limited number of occasions when the same material is 
subject to assessment under different regulations and by different panels. Such occasional duplications 
would not justify establishing a QPS list, as ensuring a uniformity of approach (and outcome) could be 
handled by existing processes within EFSA.  
The pre-assessment of even a selected number of botanicals and their preparations would be very 
demanding of resources and time. Where use is likely to be restricted to sensory purposes the QPS 
approach, while possible, offers only limited advantages over the existing procedure and may not be 
cost-effective in the short term. 
 
RECOMMENDATIONS 
The structured safety assessment scheme provides a practical method of implementing the Level A of 
the 2009 EFSA Guidance on the safety assessment of botanicals and botanical preparations intended 
for use as ingredients in food supplements. Since the scheme is not constrained by historical levels of 
exposure, it also has potential application for the safety assessment of botanicals and botanical 
preparations in general. The Scientific Committee recommends that all panels dealing with botanicals 
are made aware of and encouraged to use the scheme.  
The Scientific Committee also recommends that a reference list of botanicals that have been subject to 
a safety assessment within EFSA should be maintained. This could be of immediate value to those 
assessing the same or similar material for a different end use. It could also allow, in the longer term 
and as the number of botanicals assessed increases, a QPS list to be produced by default without the 
need for extensive pre-assessments.  
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APPENDICES 
Appendix A.  Regulatory frameworks applicable to botanicals 
If a QPS approach is to be adopted then it must be able to co-exist with requirements established by 
existing regulatory frameworks:  
 Directive 2002/46/EC sets out labelling requirements and requires that EU-wide 
maximum and minimum levels are set for each vitamin and mineral added to 
supplements. The aim is to harmonise the legislation and to ensure that these products 
are safe and appropriately labelled so that consumers can make informed choices. 
Annex I lists the vitamins and minerals which may be used in the manufacture of food 
supplements. Annex II of Directive 2002/46/EC is a list of permitted vitamin or 
mineral substances that may be added for specific nutritional purposes in food 
supplements. It also allows the use for the same purpose of “other substances” with a 
nutritional or physiological effect, but definitions of such effects are not elaborated in 
the Directive. These two annexes have been replaced by the ones from Regulation 
(EC) N° 1170/2009 that takes account of new vitamin and mineral forms evaluated by 
EFSA and comments received from interested parties.  
 Regulation (EC) N° 1925/2006 on the voluntary addition of vitamins and minerals 
and certain other substances to food (fortified food). Article 8 of Regulation, focused 
on so called “other substances”, foresees a specific procedure in order to prohibit, 
restrict or place under scrutiny a substance other than vitamins or minerals that is 
added to foods under conditions that would result in the ingestion of amounts of this 
substance greatly exceeding those reasonably expected to be ingested under normal 
conditions of consumption of a balanced and varied diet and/or would otherwise 
represent a potential risk to consumers. Member States can submit a request to the 
European Commission, providing scientific evidence allowing the Commission to 
classify a particular product in Annex III of the Regulation, in either:  
 Part A, when a harmful effect has been identified, and the addition of the products 
to food shall be prohibited, 
 Part B, when a harmful effect has been identified, and the addition of the products 
to food shall be allowed only under specific conditions, 
 Part C, if the possibility of harmful effects on health is identified but scientific 
uncertainty persists, and the substance shall be under Community scrutiny. 
Many supplements are marketed for supposed health benefits and there may be overlap with 
herbal medicinal products which are regulated in a manner distinct from that used for most 
food/feed products or ingredients. 
 Directive 2004/24/EC on “traditional herbal medicinal products” provides for 
definitions of (i) traditional herbal medicinal products, (ii) herbal medicinal products, 
(iii) herbal preparations and (iv) herbal substances. The directive introduces three 
categories of products: 1) a product can be classified under traditional medicinal use 
provisions („traditional use‟) accepted on the basis of sufficient safety data and 
plausible efficacy (at least 30 years of use including at least 15 years within the 
Community), 2) a product can be classified under well-established medicinal use 
provisions („well-established use‟). This is demonstrated with sufficient safety and 
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efficacy data, and 3) a product can be authorised after evaluation of a marketing 
authorisation application consisting of only product-specific safety and efficacy data 
(„full dossier‟).  
 
 Regulation (EC) N° 1924/2006 on nutrition and health claims made on food sets out 
the responsibility for EFSA to evaluate whether nutrition and health claims for foods 
are supported by sound science and, by doing so, to define the scientific requirements 
for the substantiation of claims. This regulation does not foresee an assessment of the 
safety of the product carrying the claim. Most of the claims submitted to the NDA 
Panel did not fulfil the criteria for scientific substantiation; their evaluation has been 
put on hold until the European Commission proposes an alternative solution. 
 
 Regulation (EC) N° 258/97 on novel foods is under a review process. It foresees a 
notification procedure to be introduced for foods which have not been traditionally 
sold in the EU but which have a safe history of safe use in third countries. “For 
traditional food from third countries, a safety assessment and management based on 
history of safe food use in the country of origin shall be introduced. If the history of 
safe food use in the country of origin has been demonstrated, and the Member States 
and EFSA do not present reasoned safety objections, based on scientific evidence, the 
food could be placed on the market by means of a notification of the food business 
operator intending to market the food” 
 
 Regulation (EC) N° 1831/2003 provides a Community procedure for authorising the 
handling and marketing and use of feed additives and to lay down rules for the post-
authorisation monitoring and labelling of feed additives and their premixtures. EFSA 
has a key role in providing independent scientific advice to support the authorisation 
process for feed additives, evaluating both safety and efficacy.  
 
 Regulation (EC) N° 2232/96 sets out the main rules on the use of flavourings in foods 
in the EU. Based on this legislation a procedure was launched to establish an EU 
positive list of flavourings which will govern the flavourings that may be added to 
foods. This Regulation was amended by Regulation (EC) N° 1331/2008 that 
introduced a common approval procedure for additives, enzymes and flavourings used 
in food, based on scientific opinions from EFSA, and Regulation N° 1334/2008 
establishing an EU list of authorised flavouring substances. Data required for the risk 
assessment of flavourings other than chemically defined flavouring substances (e.g. 
botanicals / botanical preparations from non-food sources) are outlined in the EFSA 
guidance document (EFSA CEF Panel, 2010). 
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Appendix B.  Case studies for testing the proposed approach for QPS assessment 
The following case studies are presented for the purpose to illustrate the applicability of the QPS 
approach to botanicals and botanical preparations. Data were collected for the purpose of this testing 
exercise only and are not the result of a structured data search. As such, the outcome of these QPS 
assessments should not be used elsewhere to support the safety of the botanicals and botanical 
preparations. 
 
B.1 Rosa canina  
Species, plant parts and preparations used  
Rosa canina L.; fruit, excluding the seed. 
 
Composition  
 pectin 
 sugars (sorbitol)  
 fatty acids 
 polyphenols (tannins) : proanthocyanidols and flavonoids  
 vitamin C (ascorbic acid): 0,5 to 1,7 %, beta-carotene, vitamin B1, vitamin B2, 
vitamin B3 and vitamin K  
 alpha-tocopherol,  
 other organic acids: citric, malic. 
 Minerals (Ca, Fe, K, Mn, Na, P, and Zn) 
 
Toxicity 
No toxicity reported. No reported adverse effect, apart from digestive tract and mouth irritation 
resulting from the ingestion of the hair-like layer under the flesh of the hips 
 
Use 
The fruit can be eaten as such (after having removed the hairs); or in various types of preparation such 
as dried, in infusion, soups, macerated in beer, wine, or in jam. 
 
Result of evaluation 
Adequate compositional, toxicological and use data available. No reported adverse effect.  
Proposal to grant QPS without qualification for the fruit (excluding the seed) of Rosa canina.  
 
Iteration process: 
Chemical composition of the fruits of Rosa spp. appears to be rather stable (Ercisli, 2007). 
Fruits of the following species can be safely consumed when used appropriately: Rosa alba, Rosa 
centifolia, Rosa damascena (American Herbal Products Association, 1997). 
Flower petal use of Rosa rugosa is also categorised in class 1 of the Botanical Safety Handbook  
Rose (hips and petals) have no known specific safety issues 
 
Conclusion: Adequate compositional, adequate toxicity data (mostly based on history of safe use – 
absence of reported adverse effects) adequate use data available;  
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It is therefore proposed to extend QPS status without qualification to the following species for fruit 
and petal: Rosa alba L., Rosa centifolia L., Rosa canina L., Rosa damascena L., Rosa dumalis 
Bechst., Rosa pisiformis Sosn., Rosa pulverulenta M. Bieb., and Rosa villosa L. 
 
B.2 Rosmarinus officinalis  
Species, plant parts and preparations used  
Rosmarinus officinalis L. Most scientific authorities recognise only the single species. Rosemary is 
available as various aqueous and non-aqueous preparations derived from the flowering dried twig tips, 
dried leaves, fresh leaves, the fresh aerial parts collected during flowering and the flowering branches. 
The essential oil of rosemary is distilled from the flowering tops or from stems and leaves of the plant 
taken before flowering.  
 
Composition  
Whole plant. Sufficient is known about the chemical composition of the aerial parts to recognise that 
the plant and its extracts contain substances of concern. The whole plant contains a range of 
flavonoids including diosmetin, diosmin, genkwanin and derivatives, luteolin and derivatives, 
hispidulin, neptin, nepitrin and apigenin). Other characteristic constituents are simple phenolic acids, 
phenolic diterpenes (carnosol, carnosolic acid, rosmanol, isorosmanol, epirosmanol, rosmaridiphenol, 
rosmariquinone), triterpenoids such as oleanolic and ursolic acids, α- and β-amyrin, and rofficerone 
and various hydroxycinnamic acid derivatives, e.g. rosmarinic acid. 
Extracts. Characteristic components of the essential oil are: 1,8-cineole, α-pinene, camphor, bornyl 
acetate, borneol, camphene and α-terpineol. Limonene, β-pinene, β-caryophyllene and myrcene are 
also present. Some sources indicate p-cymene and linalool as important constituents. Solvent 
extraction generates products which differ significantly in comparison with the oil obtained through 
steam distillation. Notably the di- and tri-terpenes and triterprenic acids are selectively extracted while 
the volatiles typical of the essential oil are present only in low amounts.  
 
Toxicity 
Non-aqueous solvent extracts. The potential toxicity of non-aqueous extracts has been assessed by 
EFSA (2008). Five representative extracts were studied (acetone, ethanol alone or in combination with 
hexane and supercritical carbon dioxide). Extracts were non-genotoxic in a number of bacterial and 
mammalian test systems. Data from acute mouse toxicity studies (2), 14-day range finding studies in 
rats (2) and chronic oral toxicity studies in rats (6,) were examined. NOAEL values in the range 180 – 
400 mg extract/kg BW per day were identified from the 90-day studies equivalent to 20 – 60 mg/ kg 
BW per day carnosic acid plus carnosol. A comparison of the estimated potential exposure of adults 
and children to Rosemary extracts compared to the NOAEL values indicate margins of 200 – 600 (95th 
percentile for adults) and 100 – 300 (95th percentile, pre-school children). The ANS Panel concluded 
that the use of non-aqueous solvent extracts of Rosemary could be safe in food and proposed 
maximum use levels. These have now been established in legislation (Commission Directives 
2010/67/EU and 2010/69/EU). 
Aqueous extracts. Aqueous extraction favours the solubilisation of rosmarinic acid which can reach 
10% w/w of extracts. No oral toxicity studies made with aqueous extracts of Rosemary appear to have 
been reported other than a (very) preliminary examination of effects on the male rat when 
administered over five days at a dose level of 291.2 mg and 582.4 mg/kg of body weight. Rosemary 
extract at the lower dose did not affect body or organ weights, sperm production or food intake. At the 
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higher dose there was a significant increase in seminal vesicle weight. These data are insufficient to 
derive a safe level of intake. 
Rosmarinic acid itself exhibits low toxicity (LD50 in mice is 561 mg/kg for intravenous administration) 
and is not mutagenic. It is well absorbed from the gastrointestinal tract and through the skin. However 
there are no health-based guidance values for rosmarinic acid and insufficient toxicity data from which 
a safe dose could be derived. 
Essential oil. Rosemary essential oil is contra-indicated for oral use. It is toxic even in fairly low 
doses, and a maximum safe dose has not been identified. Ingestion can result in stomach and intestinal 
irritation and kidney damage. Toxicity can be ascribed in part to camphor (and its metabolite borneol) 
and to the monoterpene ketones (limonene. α and β-pinene), which are convulsants, and have caused 
seizures in large doses. Rosemary is also an abortifacient based on its traditional use for abortion, as 
well as preliminary evidence showing embryotoxic effects. The oil provokes genotoxic and mutagenic 
effects when administered orally based on the results of a comet micronucleus assay and a bone 
marrow chromosome aberration test. Consequently use of the essential oil should be restricted to 
topical application and is not suitable for food use.  
 
Use 
Rosemary finds common use in food as a culinary herb, in beverages, and its extracts as food flavours, 
preservatives and antioxidants.   
 
Result of evaluation 
Aqueous extract: Composition well documented but, at present, there are insufficient data from which 
to derive a maximum safe intake. Based on the major component (rosmarinic acid), QPS qualification 
would have to be set based on the TTC approach. 
Non-aqueous extract: QPS with a qualification would ensure compliance with set in Commission 
Directives. 
Essential oil: Oral use contra-indicated and so should be excluded from the QPS approach. 
 
Iteration process: 
No iteration is required for the non-aqueous extracts as adequate toxicology based on a representative 
range of extracts is available on which to base an assessment.  
Sufficient compositional data for the aqueous extracts are available and can be used to identify 
components of potential concern making an iterative approach possible. However, other than 
rosmarinic acid, little data are available for the identification of safe intake levels and consequently the 
assessment of individual components is likely to default to the TTC approach.  Existing evidence 
would suggest that consumption of the essential oil is not desirable.  
 
B.3 Citrus aurantium  
Species, plant parts and preparations used  
Citrus x aurantium ssp. amara (Link) Engl. (synonym: Citrus aurantium L.)  
Dried hydro-alcoholic extracts of dried immature fruits and dried peel of the immature and mature 
fruit of Citrus x aurantium ssp. amara are available for food supplement use (Appendix A of the 
reference EFSA ESCO, 2009).  
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Composition 
Bitter orange peel 
An important constituent of the bitter orange peel is the essential oil. The pharmaceutically used bitter 
orange peel (Aurantii amari epicarpium et mesocarpium) being the dried epicarp and mesocarp of the 
ripe fruit of Citrus x aurantium ssp. amara partly freed from the white spongy tissue of the mesocarp 
and endocarp (Ph. Eur. 7, 2011) is said to contain 1.0-2.5 % essential oil (Aurantii amari aetheroleum, 
Oleum Aurantii corticis, Oleum Aurantii amari). The main component of the essential oil is limonene 
(up to 90 %). Several other monoterpenes are present (citral, linalool, linalyl-, neryl-, geranyl-, 
citronellyl-acetate). Aliphatic aldehydes and methyl-anthranilate determine the fragrance of the oil. 
Coumarins and furocoumarins are also found in the non volatile part of the essential oil. Meranzin, 
isomeranzin, epoxybergamottin and bergapten are the major coumarin- and furocoumarin derivatives 
found in the essential oil of bitter orange peel (Ph. Eur. Comment., 2012). Reported concentrations in 
bitter orange oil are 0.31 - 1.2% for meranzin, 0.15 – 0.22% for isomeranzin, 0.18 – 0.33% for 
epoxybergamottin and 0.05 - 0.1% for bergapten (Hager, 2006). 
The bitter substances of the bitter orange peel are flavonoids (flavanones glycosylated with 
neohesperidose, e.g. naringin, neohesperidin, neoeriocitrin) and tetranortriterpenes (limonoids) (Hager, 
2006).  
(-)-Synephrine ((-)-p-methylaminoethanolphenol) and octopamine are the most frequently mentioned 
biogenic amines found in bitter orange peel, however, there is no evidence that octopamine or other 
phenethylamine alkaloids are present in bitter orange peel in any appreciable levels. Analyses of the 
dried peels of fruits and of dried fruits have shown a variation of the levels of (–)-synephrine from 0.1 
to 2.0 %. (-)-synephrine and related alkaloids appear to be present in slightly higher quantities in the 
unripe fruit than in the ripe fruit. (-)-Synephrine is a sympathomimetic agent supposed to be 
responsible for the adrenergic effects of bitter orange food supplements. (NTP/NIEHS, 2004; 
Appendix A of the reference EFSA ESCO, 2009). 
 
Extracts of bitter orange fruits and their peel for food supplement use 
The extracts are usually standardised for their (-)-synephrine content. Some are additionally 
standardised for related adrenergic phenylethylamines (e.g. octopamine, hordenine). Commercial 
extracts are marketed with a content of 6-10 %, but can contain up to 95 % (-)-synephrine 
(NTP/NIEHS 2004, Blumenthal 2005). Other biologically active constituents present in the hydro-
alcoholic extract of the (unripe) fruit of Citrus aurantium include flavonoid glycosides and low levels 
of furanocoumarins (Appendix A of the reference EFSA ESCO, 2009). 
 
Toxicity 
Animal and in vitro data 
Animal experiments, such as a 28-days-NTP (National Toxicology Program)-study in rats (Hansen, 
2012), show that Citrus aurantium extracts exhibit cardiovascular effects, but they do not allow 
identification of NOAEL values since the dosages chosen were too high.  
No data are available on the genotoxicity of Citrus aurantium peel and its extracts.  
For (±)-synephrine (racemate) (120 μM to 21.53 mM) no mutations were observed in L5178Y mouse 
lymphoma cells (McGregor et al., 1988). 
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Human data 
From the human studies available, only clinical studies with a one-off intake of (-)-synephrine from 
Citrus aurantium extracts are reliable. There is a lack of suitable studies based on repeated and long-
term intake of Citrus aurantium extract with (-)-synephrine. Following a one-off dose of 54 mg of (-)-
synephrine in Citrus aurantium extract, healthy test persons without any physical exercise showed, 
compared to control, an average increase in systolic blood pressure of 7.3 mm Hg as well as slight 
acceleration of the pulse rate (Bui et al., 2006). Following administration of Citrus aurantium with 
46.9 mg of (-)-synephrine, the pulse rate increased though not the blood pressure measured (Haller et 
al., 2005). At 27 mg of (-)-synephrine in Citrus aurantium extract given as a one-off dose, there were 
no differences with regard to the length of the QT interval in the electrocardiogram (ECG), or in 
relation to systolic and diastolic blood pressure (Min et al., 2004). 
 
Use 
In traditional food the whole mature and immature fruits and their peel are used e.g. in bitter-orange 
marmalades, liqueurs and in the form of candied orange peel. Total daily intake of (-)-synephrine via 
traditional food, considering maximum concentrations of (-)-synephrine, amounts to 6.66 mg/d for 
average consumers and to 25.7 mg/d for high consumers (BfR, 2012). These values take also intake of 
(-)-synephrine via sweet oranges, lemons, mandarins and clementines and their juices into account.  
Extracts (water/alcohol) of dried immature fruits and/or peel of bitter orange have been used for food 
supplements, e.g. for herbal weight loss formulas (as an alternative to Ephedra). (-)-Synephrine is 
believed to be the active ingredient and to act as an agonist of adrenoceptors. Products are claimed to 
produce and/or maintain weight loss, improve physical fitness, and increase lean muscle mass. Such 
weight loss formulas usually contain 100-200 mg of bitter orange extract (NTP/NIEHS, 2004; 
Blumenthal, 2005). Often these products contain in addition caffeine which is expected to enhance the 
cardiovascular effects of (-)-synephrine (Health Canada, 2011; Appendix A of the reference EFSA 
ESCO, 2009).  
In a medicinal product, the racemic mixture of (±)-synephrine having only about half of the biological 
activity of (-)-synephrine has been used in the form of the tartrate to treat cardiovascular disturbances 
(Rote Liste, 1995; Martindale, 2011; Stohs and Preuss, 2012). The recommended single dose is 
equivalent to 34.5 - 52 mg (-)-synephrine given three times daily, equivalent to a total dose of 103.5 - 
155 mg (-)-synephrine/d. 
 
Result of evaluation 
Following the application of the flow diagram (Figure 1), (-)-synephrine extracted from C. aurantium 
can be classified as follows:  
 thresholded substance 
 no established health-based guidance value 
 no sufficient toxicity data available to estimate a safe level of intake, but there is a history of 
use via traditional food without any reported adverse effect. It should however be underlined 
that absence of evidence for adverse effect can not be taken as an evidence for the absence of 
adverse effect(s). Considering the doses showing a pharmacological effect in humans and the 
levels of exposure resulting from the traditional use of C.aurantium preparations, there is a 
biological plausibility for an adverse health effect, although it has not been picked up by 
historical data. 
A diversity of coumarin- and furocoumarin derivatives is described as components of the essential oil 
of C. aurantium. Theoretically these compounds could occur as minor impurities in the botanical 
preparation(s) considered, although no information could be retrieved to confirm their presence in C. 
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aurantium water/alcohol extracts. Still, coumarin and furocoumarin derivatives should be considered 
as substances of interest for the QPS assessment and run through the flow diagram (Figure 1). 
 
Conclusions of the assessment:  
 (-)-Synephrine is regarded as the principal substance of concern (grouped together with related 
adrenergic phenylethylamines, e.g. octopamine, hordenine). A diversity of coumarin- and 
furocoumarin derivatives is regarded as minor impurities which theoretically may occur. Their 
intake levels should stay below possibly existing health based guidance values, or below the 
relevant TTC values in the absence of such health-based guidance values. 
 If basing the assessment on the history of use without any reported adverse effect, and in line 
with the level A of the SC guidance for the safety assessment of botanicals and botanical 
preparations (EFSA, 2009), dried hydro-alcoholic extracts of dried immature fruits and dried 
peel of the immature and mature fruits of Citrus x aurantium ssp. amara (Link) Engl. are 
suitable for QPS status, provided that the use of extracts is restricted to levels where (-)-
synephrine intakes in the form of food supplement(s) do not exceed significantly historical 
intake levels from traditional foods.  
 If one decide to ignore the history of use, considering rather the plausibility for undetected 
long term adverse effects linked to (-)-synephrine, dried hydro-alcoholic extracts of dried 
immature fruits and dried peel of the immature and mature fruits of Citrus x aurantium ssp. 
amara (Link) Engl. would then be excluded from QPS status. 
 
Iteration process: 
Extension of the QPS status for the dried hydro-alcoholic extracts to other preparations or the entire 
immature or mature dry or fresh fruits of Citrus x aurantium ssp. amara (Link) Engl. including their 
peels 
The extension seems to be possible whereby this still needs verification examining the existing 
database.  
 
Extension of the QPS status of entire immature or mature dry or fresh fruits Citrus x aurantium ssp. 
amara (Link) Engl. including their peels to other parts of Citrus x aurantium ssp. amara (Link) Engl. 
The question of whether extension of the QPS status to other parts of the plant used, such as leaves 
(Citri aurantii folium) or flowers (Aurantii amari flos), is possible has to be evaluated based on 
relevant literature, e.g. comparing the composition data of the dried fruits and their peels with those of 
relevant other plant parts.  
 
Extension of the QPS status of entire immature or mature dry or fresh fruits of Citrus x aurantium ssp. 
amara (Link) Engl. including their peels to fruits of other subspecies of Citrus aurantium L. or of 
other species of the genus of Citrus 
Other subspecies of Citrus aurantium L., e.g. Citrus x aurantium ssp. bergamia (Risso & Poit.) Engl. 
(bergamot orange) or Citrus aurantium var. voangkely H. Perrier, are described. The genus Citrus 
comprises different species including many hybrids of which some are the source of edible, others of 
non edible fruits. According to Tanaka (1954) the term Citrus is a genus comprising 145 species (and 
12 additional new species) of which the fruits are edible or not edible. According to Swingle (1967) 
the term Citrus is more specifically defined as a subgenus comprising only 16 species which are all the 
source of edible fruits with the exception of the species of Citrus tachibana (Hager, 2006). 
Besides the fruits of Citrus aurantium L. also the fruits of other Citrus species may contain (-)-
synephrine. Arbo et al. (2008) identified (-)-synephrine in the fruits of all Citrus species they 
investigated: Citrus aurantium L., C. sinensis Osbeck, C. deliciosa Ten, C. limon Burm and C. limonia 
Osbeck. (-)-Synephrine was also found by Xing-Qian et al. (2011) in the fruits of all nine mandarin 
cultivars they analysed: C. unshiu var. praecox Tanaka cv Nichinan No. 1, C. unshiu var. praecox 
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Tanka cv Miyagawa wase, C. unshiu Marc. cv Yamada, C. unshiu Marc. cv Owari, C. poonensis Hort. 
ex Tanaka, C. erythrosa Hort. ex Tanka, C. tardiferax Hort. ex Tanka, C. succosa Hort. ex Tanaka, C. 
suavissima Hort. ex Tanaka. 
(-)-Synephrine has also been detected by Inafuku-Teramoto et al. (2011) in the peel of the fruits of all 
the analysed Citrus species: C. depressa, C. madurensis, C. rokugatsu, C. oto, C. keraji, C. nobilis, C. 
tankan, C. tangerine. 
Other typical components of fruits belonging to the genus of Citrus in a wider sense are (i) essential 
oils and their characteristic ingredients such as terpenes, (ii) typical flavonoids such as a diversity of 
flavanones, flavones and flavonoles, (iii) coumarin derivatives such as different furocoumarins and 
hydroxycoumarins, and (iv) a diversity of limonoids (Hager, 2006).  
In view of the expected diversity in composition of the fruits of the numerous Citrus 
species/subspecies including all hybrids, and the biological activities of the components which may be 
present, it can only be decided on a case by case basis for each species and subspecies if it will be 
justified to extrapolate the above described QPS approach to it and if an implication of additional or 
other qualifications is necessary. A literature research would be needed regarding e.g. the composition 
of the fruits of the different individual Citrus species/subspecies to conclude which of them could be 
included in the QPS approach. This would be most promising in a first step for the edible fruits of 
Citrus species/subspecies. 
 
B.4 Foeniculum vulgare  
Species, plant parts and preparations used  
For Foeniculum vulgare two varieties can be defined including Foeniculum vulgare Mill. var. dulce 
and Foeniculum vulgare Mill. var. vulgare. From both species preparations based on the essential oil 
as well as preparations containing water based extracts might be considered. 
 
Composition  
Essential oil 
The essential oil of both species is known to contain substances of concern including trans-anethole 
and estragole (SCF, 2001a; SCF, 2001b; Council of Europe, 2006). The essential oil also contains 
estragole which is known to be genotoxic and carcinogenic. 
Water based extracts 
Given the limited water solubility of these compounds of concern their concentrations in water 
extracts is expected to be significantly lower than in the essential oils. 
 
Toxicity 
For trans-anethole JECFA derived a temporary ADI of 0-2.0 mg/kg bw (JECFA, 1998), which can be 
used to define whether exposure of proposed uses and use levels will be safe and can be assigned QPS 
status with defined exposure restrictions. 
For estragole there are carcinogenicity data from which a BMDL10 could be derived and one could use 
the MOE approach to characterise the level of concern resulting from the exposure to this substance 
through food. However, given the recommendation of the Scientific Committee to not introduce into 
the food chain substances that are known to be genotoxic and carcinogenic (EFSA, 2005), preparations 
from Foeniculum vulgare containing estragole will have to be excluded from the QPS approach and 
therefore subject to a case-by-case assessment 
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Use 
Fennel based teas are traditionally used in many parts of Europe including France, Germany, Austria, 
Czech Republic and Poland in for example the symptomatic treatment of digestive disorders 
alleviating mild spasmodic gastro-intestinal ailments and for the relief of symptoms during 
inflammations of mucous membranes of the upper respiratory tract (EMA, 2008). Homemade fennel 
tea is often used as a remedy for gastrointestinal complaints in infants and young children (Crotteau et 
al., 2006; Perry et al., 2011). In addition various fennel-based food supplements are on the market 
containing for example the essential oil, dried extract or seeds. 
 
Result of evaluation 
Given the recommendation of the Scientific Committee to not introduce into the food chain substances 
that are known to be genotoxic and carcinogenic (EFSA, 2005), preparations from Foeniculum 
vulgare containing estragole are excluded from the QPS approach and should be subject to a case-by-
case assessment. In this particular case, it should be noted that the level of estragole extracted into the 
essential oils of Foeniculum vulgare species will be higher than the levels extracted into water based 
preparations. For risk management purposes, it may be of interest to assess preparations of these 
species on a case-by-case basis, using the carcinogenicity data for estragole from which a BMDL10 
could be derived and for which it is therefore possible to apply the MOE approach. The fact that some 
preparations e.g. essential oils of Foeniculum vulgare and Ocimum tenuiflorum species will show 
higher levels of estragole than the levels extracted into (traditional) water based preparations should 
then be taken into account. 
 
Iteration process: Given that different preparations (e.g. fine cut, whole fruits) and two varieties exist 
for Foeniculum vulgare generally used for fennel based teas, QPS status could be considered only if 
specific preparations of one or the other variety are demonstrated to be exempt of estragole.  
 
B.5 Camellia sinensis 
Species, plant parts and preparations used  
Camellia sinensis (L.) O. Kuntze 
Parts used and preparations thereof: Young leaves and leaf buds are used unfermented and dried to 
produce traditional “green tea” as the basis for traditional aqueous green tea infusions. Leaves and leaf 
buds are also used to produce the so called “dried aqueous green tea extracts” for use in food 
supplements. (Appendix B of the reference EFSA ESCO, 2009).  
 
Composition 
Green tea 
Polyphenols: Green tea contains a diversity of polyphenolic compounds, which account for up to 30% 
of the dry weight of green tea leaves. Most of the polyphenols in green tea are flavanols, commonly 
known as catechins. The primary catechins in green tea are (-)epicatechin (EC), (-)epicatechin-3-
gallate (ECG), (-)epigallocatechin (EGC), and (-)epigallocatechin-3-gallate (EGCG). Furthermore 
(+)catechin (C), (+)gallocatechin (GC), (-)gallocatechingallate (GCG), (-)catechingallate (CG), occur 
in green tea. Young leaf green tea contains lower levels of EGCG and total catechins than old leaf 
green tea (Lin et al., 2003).  
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Purine alkaloids: caffeine (previously referred to as theine or teine; depending upon the development 
stage of the leaves, 2.9-4.2%, content declining with age), theobromine (0.15-0.2%), theophylline 
(0.02-0.04%). 
Amino acids: The total amino acids content in green tea amounts to 4%, including the tea 
characteristic L-theanine as a major component (2% of green tea). 
Green tea extracts 
Green tea extracts, e.g. traditional aqueous green tea infusions or dried green tea extracts, vary in their 
compositions depending on the green tea used and the conditions of the manufacturing procedure. 
Table 1:  Contents (mean values of 3-5 determinations) of catechins in a Chinese and a Japanese 
green tea infusion (preparation: 1g tea leaves were brewed with 100 ml boiling water and decanted 
after 5 minutes). The (+)-catechin contents are below the detection limit (10 μg/ml). a = percentage 
referred to total catechins. (Khokar et al., 1997). 
Green tea 
infusions 
EC  
(mg/100 ml)  
ECG  
(mg/100 ml)  
EGC  
(mg/100 ml)  
EGCG  
(mg/100 ml) 
Total catechins  
(mg/100 ml)  
China  4.7 (9.1 %)
a
  4.4 (8.5 %)
a
  16.3 (31.7 %)
a
  26.3 (51.1 %)
a
  51.5  
Japan  9.4 (11.1 %)
a
  5.9 (6.9 %)
a
  28.7 (33.8 %)
a
  40.8 (48.1 %)
a
  84.9  
 
The manufacturing processes for “dried green tea extracts” for use in food supplements vary in 
extraction techniques and manufacturing procedures and are not uniform. They may differ from the 
traditional green tea infusion, e.g. in the solvent being different from water, in the source (e.g. fresh 
leaves instead of green tea), in extraction conditions (e.g. degree of comminution, concentration ratios, 
temperature, duration, stirring) and in fractionation procedures concentrating active compounds 
(Appendix B of the reference EFSA ESCO, 2009). 
 
Toxicity 
Dried green tea extracts 
Toxicokinetic results in animals and humans show that administration of concentrated green tea 
extracts under fasting conditions leads to a significant increase of plasma concentrations and 
bioavailability of EGCG compared to administration with feed or food (Appendix B of the reference 
EFSA ESCO, 2009).  
 
Animal and in vitro data 
In three subchronic studies in rats and fasting beagle dogs, NOAELs ranging from 40 to 50 mg 
EGCG/kg body weight per day have been found in relation to organ damage including hepatic 
necrosis (McCormick et al., 1999; Johnson et al., 1999; Isbrucker et al., 2006; Appendix B of the 
reference EFSA ESCO, 2009). 
A green tea preparation (consisting of 85 to 95% total catechins (by weight) and more than 55% 
EGCG) was negative in the Ames test, the rat micronucleus assay, the UDS test, and the transgenic 
mouse mutation assay, but positive in the mouse lymphoma mutation assay (FDA, 2006; Chang et al., 
2003). In an oral (gavage) carcinogenicity study, the same preparation was administered daily for 26 
weeks to p53 transgenic mice at doses up to 500 mg/kg/day. The treatment was not associated with an 
increased incidence of either neoplastic or non-neoplastic lesions in the organs and tissues examined 
(FDA, 2006).  
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Human data 
The analysis of the available human data (up to 2009) shows that in more than 30 cases, an association 
was seen between the intake of large amounts of green tea-derived products and the occurrence of, in 
some cases, severe liver damage. In many cases of these liver disorders dried green tea extracts with 
high EGCG contents were taken in capsule form over several months as a medicinal product or food 
supplement to support weight-loss. Concerning the treatment with an oral phytotherapeutical drug the 
daily intake of 2 capsules to 5 capsules (187.5 – 468.75 mg EGCG/ day), mostly 4 capsules (375 mg 
EGCG/ day) was associated with liver damage. A causal relationship has to be regarded as probable in 
7 cases and as possible in 27 cases (Sarma et al., 2008; Appendix B of EFSA ESCO, 2009). 
 
Use 
Worldwide long-time consumption of traditional green tea infusions has to be taken into consideration. 
Beverages prepared from dried aqueous green tea extracts (ready to drink or prepared from instant 
preparations) show a similar composition, i.e. do not exceed the concentrations of polyphenols in 
traditional infusions, and are therefore under qualitative and quantitative aspects equivalent to 
traditional green tea infusions.  
Exposure data exist for traditional uses as a stimulant drink in the form of green tea infusions (see 
Table 4 of Appendix B of the reference EFSA ESCO, 2009). 
Food supplements or related products on the basis of dried green tea extracts, e.g. for the purpose of 
supporting weight reduction, have been described with a daily dose representing the equivalent of 
minimum 150 mg caffeine, 115-270 mg EGCG, and 375 mg catechins) (Appendix B of the reference 
EFSA ESCO, 2009). 
A medicinal weight-loss product containing a high-dosed hydroalcoholic extract of green tea was 
marketed only until April 2003, when the French and Spanish authorities suspended the market 
authorisation because of hepatotoxic side-effects (AFSSAPS, 2003; Sarma et al., 2008). 
 
Result of evaluation 
(-)Epigallocatechin-3-gallate (EGCG) is the major catechin in green tea extracts and is associated with 
liver toxicity seen in animals and humans after exposure with dried green tea extracts under certain 
conditions. 
Classification of EGCG found in dried green tea extracts for food supplement use according to the 
decision tree:  
 thresholded substance 
 established health-based guidance value 
In the evaluation of dried green tea extracts for food supplement use, reference to a NOAEL ranging 
from 40 to 50 mg EGCG/kg body weight per day according to the results of three out of five 
subchronic studies is made (Appendix B of the reference EFSA ESCO, 2009). By applying a safety 
factor of 100, a maximum intake of 0.5 mg EGCG/kg body weight per day with dried aqueous green 
tea extracts used in food supplements can be accepted under the conditions that the extracts are 
manufactured under the same extraction conditions as applied in the traditional preparation of green 
tea infusions and that the extracts are not used for products for weight reduction purposes (Appendix B 
of the reference EFSA ESCO, 2009).  
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Conclusion of the assessment: apart from the worldwide long-time consumption of traditional green 
tea infusions
4
, which is regarded as safe
5
, QPS status could be granted to dried extracts of unfermented 
and dried leaves and leaf buds of Camellia sinensis (L.) O. Kuntze with the following qualifications: 
 a maximum intake of 0.5 mg EGCG/kg body weight per day with dried aqueous green tea 
extracts used in food supplements. 
 the extracts are manufactured under the same extraction conditions as applied in the traditional 
preparation of green tea infusions. 
 The attention of the risk manager should be brought to the increased bioavailability of EGCG 
when taken in the fasting state. 
 In addition the possible presence of caffeine in the dried extracts has to be taken into 
consideration.  
 
Iteration process: 
Extension of the QPS status of dried aqueous extracts of unfermented dried leaves and leaf buds of 
Camellia sinensis (L.) O. Kuntze to the entire unfermented dried or fresh leaves and leaf buds of 
Camellia sinensis (L.) O. Kuntze 
Considering the available database this seems not to be possible. 
 
Extension of the QPS status of dried aqueous extracts of unfermented dried leaves and leaf buds of 
Camellia sinensis (L.) O. Kuntze to extracts of a) fermented/semifermented dried leaves and leaf buds 
or b) of other parts of Camellia sinensis (L.) O. Kuntze  
Depending on the manufacturing process mainly three different traditional tea products are prepared 
from the leaves and leaf buds of C. sinensis: Green tea, black tea and oolong tea. While “green tea” is 
produced without fermentation and thus preventing oxidation of the polyphenolic components, “black 
tea” manufacture is carried out by fermentation ensuring a high degree of enzymatically catalysed 
aerobic oxidation of the polyphenols followed by a series of chemical condensations. In “oolong tea”, 
a semifermented tea, polyphenols are partially oxidized. Thus unfermented, semifermented and 
fermented dried leaves and leaf buds of C. sinensis differ in their chemical composition as do their 
extracts. 
The question of whether extension of the QPS status to extracts of fermented/semifermented dried 
leaves and leaf buds or of other parts of the plant, such as blossoms or roots, is possible, has to be 
evaluated based on relevant literature and comparing the composition data of the botanicals and their 
extracts.  
 
Extension of the QPS status of dried aqueous extracts of unfermented and dried leaves and leaf buds 
of Camellia sinensis (L.) O. Kuntze to extracts of leaves and leaf buds of other species of the genus 
Camellia 
The genus Camellia comprises about 80 different species (Hager, 2006) of which only the species 
Camellia sasanqua Thunb. containing sasanqua triterpenoid saponins, is listed besides Camellia 
sinensis (L.) O. Kuntze in the EFSA Compendium of botanicals reported to contain naturally 
occurring substances of possible concern for human health when used in food and food supplements 
(EFSA Scientific Committee, 2012). In view of the expected diversity in composition of the leaves 
and leaf buds of the numerous Camellia species and the biological activities of the components which 
                                                     
4
 Beverages prepared from dried aqueous green tea extracts (ready to drink or prepared from instant 
preparations), that have a similar composition and do not exceed the concentrations of polyphenols in traditional 
infusions, are regarded to be equivalent to traditional green tea infusions 
5
 
2
 This conclusion holds provided that pregnant and nursing mothers as well as children and other caffeine 
sensitive persons consume the beverage in moderation or abstain from it (general recommendation for caffeine 
containing beverages postulated to be common knowledge). 
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may be present, it can only be decided on a case by case basis for each species if it will be justified to 
extrapolate the above described QPS approach to it and if an implication of additional or other 
qualifications is necessary. A literature research would be needed regarding e.g. the composition of the 
leaves and leaf buds of the different individual Camellia species to conclude which of them could be 
included in the QPS approach.  
 
B.6 Ocimum tenuiflorum  
Species, plant parts and preparations used  
Ocimum tenuiflorum L. (Synonym Ocimum sanctum L.) 
Parts used: Leaf: spice (Thai cuisine) but also used in traditional systems like the Indian Ayurveda 
(Pattanayak et al. 2010). Essential oil from leaf (EFSA, 2012).  
 
Composition  
Leaf: 2% Essential oil (EFSA 2012), 2% ursolic acid, a pentacyclic triterpenoid (3β)-3-hydroxy-urs-
12-en-28-oic acid) (Silva et al. 2008).The essential oil contains eugenol (up to 62%) and 
methyleugenol (up to 86%), 7-25% methylchavicol (estragole) and 7-23% 1,8-cineole (eucalyptole) 
(EFSA, 2012, Zheljazkov et al. 2008). The leaf is also reported to contain alkaloids and saponins 
(EFSA, 2012). 
 
Toxicity 
Reproductive toxicity 
Leaves are used as a human abortifacient in India (Prakash & Gupta 2005, Ahmed et al. 2002b). There 
is no information on the doses used. 
A preliminary study using fresh leaves 1 g/kg body weight/day resulted in vaginal bleeding. Feeding 
with fresh leaves of O. tenuiflorum (1 g/kg bw) twice a week for one month in adult rabbits caused 
significant changes in the histology of the testis, epididymis, uterus and ovary. Pregnancy and 
subsequent delivery occurred only in those rabbits which were allowed to mate one month after the 
stoppage of the leaves feeding period as compared to those rabbits allowed to mate directly after the 
stoppage of the feeding period (Reghunandan et al. 1997). This indicates that the effect under certain 
condition might be reversible (EFSA ESCO, 2009).  
Other studies in male rats, mice and rabbits have shown various effects on male fertility, decreased 
sperm count, weight changes and/or histological effects on testes or accessory sex organs after peroral 
intake of the dried leaf and stem, with benzene extracts and water extracts (Khanna et al. 1986, Kantak 
and Gogate 1992, Ahmed et al. 2002a,b, Ahmed et al. 2009, Sethi et al. 2010, Pragya et al. 2012). The 
dried leaf and stem caused effect on oestrus cycle and fertility in female rats (Khanna et al. 1986).  
Genotoxicity and carcinogenic effects 
The genotoxicity and carcinogenicity of methyleugenol have been well documented (SCF 2001b, 
Rietjens et al. 2008). 
 
Use: 
No exposure data exist for use as a spice/culinary herb in Thai cuisine.  
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Therapeutic/medicinal use: Fresh leaves 2 g/kg body weight/day for 30 days (Sethi et al. 2008). Dried 
leaves: 300-2000 mg/day as a single dose and 600-2000 mg in multiple doses. Infusions 2 g dried 
leave per cup of water or 2.5 g dried leaf/day. Leaf juice: 10-20 ml of fresh leaf juice (EFSA, 2012). 
No information on recommended dose levels of other plant parts.  
 
Result of evaluation 
The plant species and the plant parts are well-defined (first box in flow diagram).  
The chemical analytical data do not provide adequate compositional data. The chemical(s) of concern 
for the reproductive effects have not been pinpointed. The information on 
compositional/toxicological/use data is insufficient. Moreover, O. tenuiflorum‟s leaves are reported to 
contain genotoxic and carcinogenic substances. O. tenuiflorum L. (leaf) is therefore excluded from the 
QPS approach. 
 
Iteration process: 
Not applicable due to inadequate compositional/toxicological/use data. 
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GLOSSARY  
History of safe use The safety of the food in question is confirmed with 
compositional data and from experience of use and continued 
use for at least 25 years in the customary diet of a large part 
of the population of a country 
Council of the European Union (2009). Proposal for a Regulation 
of the European Parliament and of the Council on novel foods and 
amending Regulation (EC) No 1331/2008 (common position) 
 
Margin of exposure Ratio of the no-observed-adverse-effect level or benchmark 
dose lower confidence limit for the critical effect to the 
theoretical, predicted or estimated exposure dose or 
concentration. 
FAO/WHO International Programme on Chemical Safety, 2009. 
Environmental Health Criteria 240 – Principles and Methods for 
the Risk Assessment of Chemicals in Food. ISBN: 978-92-4-
157240-8 
Margin of safety The margin between the health-based guidance value 
(reference dose) and the actual or estimated exposure dose or 
concentration.  
FAO/WHO International Programme on Chemical Safety, 2009. 
Environmental Health Criteria 240 – Principles and Methods for 
the Risk Assessment of Chemicals in Food. ISBN: 978-92-4-
157240-8 
 
ABBREVIATIONS 
ANS Panel on Food Additives and Nutrient Sources Added to Food MOS Margin of Safety 
BMDL10 Lower confidence bound of the benchmark dose for a 10% response NDA Panel on Dietetic Products, Nutrition and Allergies 
CEF Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids  QPS Qualified Presumption of Safety 
FEEDAP Panel on Additives and Products or Substances used in Animal Feed  (Q)SAR (Quantitative) Structure Activity Relationship 
MOA Mode of Action SC Scientific Committee 
MOE Margin of Exposure TTC Threshold of Toxicological Concern 
 
